Journals / Journal of Neurological Sciences (Turkish) / 2007 / Cilt: 24 - Sayı: 1

Lenalidomide etkisinin glioblastoma hücreleri üzerinde in vitro koşullarda değerlendirilmesi

Evaluation of lenalidomide activity on glioblastoma cell lines in vitro

Pages
29–37
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It may not be a therapeutic agent in the in the absence of γ-irradiation for the treatment of GBM.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Thalidomide analog, Lenalidomide (Revlimid®) is a chemotherapeutic agent.
📊
Key Findings & Data:In this study, lenalidomide was used in human glioblastoma multiforme (GBM) cell lines to determine its pro-apoptotic, anti-proliferative and radiosensitizing properties.Methods: The GBM cells were treated with lenalidomide [0, 1, 5, 30, 60 µM] before ultravioletB (UVB) [0, 50, 100 mj] or γ -irradiation [0, 5, 20 Gy], and kept in drug for 5 days.
💡
Conclusion & Impact:It may not be a therapeutic agent in the in the absence of γ-irradiation for the treatment of GBM.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: Thalidomide analog, Lenalidomide (Revlimid®) is a chemotherapeutic agent. In this study, lenalidomide was used in human glioblastoma multiforme (GBM) cell lines to determine its pro-apoptotic, anti-proliferative and radiosensitizing properties.Methods: The GBM cells were treated with lenalidomide [0, 1, 5, 30, 60 µM] before ultravioletB (UVB) [0, 50, 100 mj] or γ -irradiation [0, 5, 20 Gy], and kept in drug for 5 days. Viable cell numbers were determined by trypan blue exclusion. The cell proliferation index was assessed by[ 3H]-Thymidine incorporation. Apoptosis was assessed by flow cytometry with Sub G0 gating and the activation of caspase-8 and caspase-9 after the treatments were completed. Results: Lenalidomide alone or in combination with UVB or γ-irradiation did not have a significant effect on cell death. Lenalidomide had minimal synergistic effect with γ-irradiation to reduce cell growth. Lenalidomide when used alone had an insignificant stimulatory effect on cell proliferation in GBM cells at doses 1-30 µM. Lenalidomide did not activate caspase-8 or caspase-9 pathways. Conclusions: Lenalidomide had a weak synergistic effect with γ-irradiation in decreasing cell growth in vitro. It may not be a therapeutic agent in the in the absence of γ-irradiation for the treatment of GBM.

Özet

Amaç: Kemoterapide kullanılan ilaçlardan biri olan Thalidomide analogu Lenalidomide’in insan glioblastoma multiforme (GBM) hücreleri üzerinde pro-apoptotik, çoğalmayı azaltıcı ve radyasyona karşı duyarlılığı artırıcı etkilerinin araştırılması Yöntem: GBM hücreleri lenalidomide’e [0, 1, 5, 30, 60 µM dozlarında] 5 gün boyunca maruz bırakıldı ve ardından ultravioletB (UVB) [0, 50, 100 mj] veya γ-radyasyonu [0, 5, 20 Gy] verildi. Bu işlemler sonrası yaşayan hücreler “trypan blue exclusion” testi ile sayıldı. Çoğalma endeksi timidin inkorporasyonu ile, apoptoz ise sub G0 kestinin bakıldığı akım sitometre ve kaspaz aktivasyonu ile değerlendirildi.Bulgular: Lenalidomide tek başına veya UVB veya g-radyasyon ile birleştirildiğinde hücre ölümüne ek katkıda bulunmadı. Sadece γ-radyasyon ile minimal bir sinerjistik etki göstererek hücre çoğalmasını azalttı. Önemlilik derecesine ulaşmasa bile tek başına 1-30 µM dozlarda verildiğinde hücrelerin çoğalmasına katkıda bulundu. Lenalidomide apoptoz ile sonuçlanan kazpaz yollarını aktive etmedi. Sonuç: Lenalidomide in vitro deney koşullarında γ-radyasyon ile verildiğinde minimal bir sinerjistik etkiye sahiptir. Lenalidomide GBM tedavisinde γ -radyasyon yokluğunda etkin bir ajan olmayabilir.

🔖

Cite This Article

MUT, M., REDPATH, G., POLAR, G., CARPENTER, J. E., LARNER, J., SCHIFF, D., SHAFFREY, M. E. (2022). Lenalidomide etkisinin glioblastoma hücreleri üzerinde in vitro koşullarda değerlendirilmesi. Journal of Neurological Sciences (Turkish), Cilt: 24 - Sayı: 1, 29–37. https://ajindex.com/articles/565590

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Baumann F, Bjeljac M, Kollias SS, Baumert BG, Brandner S, Rousson V, Yonekawa Y, Bernays RL Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme J Neurooncol 2004, 67:191-200 2) Bigner DD, Bigner SH, Ponten J, Westermark B, Mahaley MS, Ruoslahti E, Herschman H, Eng LF,Wikstrand CJ. Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas J Neuropathol Exp Neurol 1981, XL: 201–229 3) Bongcam-Rudloff E, Nister M, Betsholtz C, Wang JL, Stenman G, Huebner K, Croce CM, Westermark B. Human glial fibrillary acidic protein: complementary DNA cloning, chromosome localization, and messenger RNA expression in human glioma cell lines of various phenotypes Cancer Res 1991, 51:1553–1560 4) Chang SM, Lamborn KR, Malec M, Larson D, Wara W, Sneed P, Rabbitt J, Page M, Nicholas MK, Prados MD. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme Int J Radiat Oncol Biol Phys 2004, 60: 353-7 5) Dredge K, Dalgleish AG, Marriott JB Thalidomide analogs as emerging anti-cancer drugs Anticancer Drugs 2003, 14: 331-5 6) Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults Cancer 1993, 71:2585–2597 7) Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas J Clin Oncol 2000, 18:708-15 8) Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas J Clin Oncol 2003, 21:2299-304 9) Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC. Thalidomide and its analogs overcome drug resistance of human multiple myeloma Cells to conventional therapy Blood 2000, 96:2943-50 10) Hussaini IM, Carpenter JE, Redpath GT, Sando JJ, Shaffrey ME, Vandenberg SR. Protein kinase C-eta regulates resistance to UVB- and gamma-irradiation-induced apoptosis in glioblastoma cells by preventing caspase-9 activation Neuro-oncol 2002, 4: 9-21 11) Kruidering M, Evan GI. Caspase-8 in apoptosis: the beginning of "the end"? IUBMB Life 2000, 50: 85-90 12) Lederman G, Wronski M, Arbit E, Odaimi